Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report
Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.
It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.
If you have any feedback on the new format please contact the Project Manager for this appraisal.
01. Manufacturer Patient Access Scheme (PAS) submitted by Celgene
02. Evidence Review Group critique of manufacturer PAS prepared by Kleijnen Systematic Reviews
03. Additional evidence provided by Celgene in response to Committee and NICE request for further cost-effectiveness analysis
04. ERG critique of additional evidence prepared by Kleijnen Systematic Reviews
05. Comments received from clinical expert Professor David Bowden
Myelodysplastic syndrome (deletion 5q) - lenalidomide: evaluation report
20 May 2014 (2.53 Mb 33 sec) |
This page was last updated: 19 May 2014